BFRI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States...

Stats
Today's Volume	28 084.00
Average Volume	119 752
Market Cap	5.24M
EPS	$0 ( 2024-05-15 )
Next earnings date	( $-1.190 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0160 (1.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-18	Luebbert Hermann	Buy	4 771	Common Stock
2024-05-18	Luebbert Hermann	Sell	4 771	Restricted Stock Units
2023-07-03	Lanckriet Heikki	Buy	0
2023-05-18	Monaco Erica L.	Buy	76 336	Common Stock
2023-05-18	Monaco Erica L.	Sell	76 336	Restricted Stock Units

INSIDER POWER
16.11
Last 26 transactions
Buy: 1 252 764 \| Sell: 176 527

Biofrontera Inc. Correlation

10 Most Positive Correlations
GDC	0.939
CRGX	0.935
NXT	0.922
HPCO	0.913
NXU	0.908
ATLCL	0.903
CWD	0.903
BFRGW	0.902
FFRHX	0.897
AWIN	0.89

10 Most Negative Correlations
OZEM	-1
INDH	-0.963
CCSB	-0.959
GECCI	-0.936
NEWZ	-0.929
PSTR	-0.927
OPTXW	-0.908
BOTT	-0.901
OPTZ	-0.889
BKHAU	-0.889

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biofrontera Inc. Financials

Annual	2023
Revenue:	$34.07M
Gross Profit:	$15.56M (45.68 %)
EPS:	$-13.02

FY	2023
Revenue:	$34.07M
Gross Profit:	$15.56M (45.68 %)
EPS:	$-13.02

FY	2022
Revenue:	$28.67M
Gross Profit:	$13.49M (47.04 %)
EPS:	$-0.610

FY	2021
Revenue:	$24.04M
Gross Profit:	$11.30M (47.00 %)
EPS:	$-3.25

Financial Reports:

No articles found.

Biofrontera Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.